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to examine the quality of care for AECOPD and to provide 
specific recommendations for the management of severe 
AECOPD in Switzerland.  Methods: A total of 295 patients 
requiring hospital admission to 19 Swiss hospitals due to ex-
acerbation of COPD during a predefined 60 days in 2011 
were included in the study. We compared the Swiss data to 
the official GOLD 2010 recommendations and to the results 
of the other European countries.  Results: Approximately 
43% of the Swiss patients with severe AECOPD were current 
smokers at hospital admission, compared to 33% of the pa-
tients in other European countries ( p < 0.001). In Switzerland 
and in Europe, spirometry data were not available for most 
patients at hospital admission (65 and 60%, respectively; 
p = 0.08). In comparison to other European countries, anti-
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 Abstract 
 Background: The European COPD Audit initiated by the 
European Respiratory Society (ERS) evaluated the manage-
ment of hospital admissions due to exacerbation of chronic 
obstructive pulmonary disease (COPD) in several European 
countries. Data on the treatment of severe acute exacerba-
tions of COPD (AECOPDs) in Switzerland are scarce.  Objec-
tives: In light of the GOLD 2010 guidelines, this work aims 
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biotics were prescribed 14% less often in Switzerland ( p < 
0.001). Only 79% of the patients in the Swiss cohort received 
treatment with a short-acting bronchodilator at admission. 
 Conclusions: Considering the overall high standard of health 
care in Switzerland, in light of the GOLD 2010 guidelines we 
are able to make 7 recommendations to improve and stan-
dardize the management of severe AECOPD for patients 
treated in Switzerland.  © 2017 S. Karger AG, Basel 
 Introduction 
 Chronic obstructive pulmonary disease (COPD) re-
mains associated with high morbidity and mortality. 
According to the World Health Organisation (WHO), in 
2020 COPD will rank fifth worldwide in burden of dis-
ease. Furthermore, it is a leading cause of death and ex-
pected to become the seventh leading cause of disability-
adjusted life years lost  [1, 2] . In Switzerland, around 
200,000–300,000 patients suffer from COPD of GOLD 
(Global Initiative for Chronic Obstructive Lung Disease) 
stage II or higher  [3] .
 Many COPD patients experience exacerbations of the 
disease. The GOLD defines COPD exacerbation as “an 
acute event characterized by a worsening of the patient’s 
respiratory symptoms that is beyond normal day-to-day 
variations and leads to change of the medication”  [4] . The 
clinical presentation for exacerbations of COPD is het-
erogeneous and can be triggered by infectious and non-
infectious conditions. Determining the cause of the exac-
erbation is challenging, and thus far there are no tools 
capable of diagnosing or predicting the duration of an 
acute exacerbation of COPD (AECOPD)  [5] . AECOPDs 
requiring hospital admission are considered to be severe 
and are associated with increased mortality  [6] as well as 
with an increased mortality risk of 30–43% within the 12 
months following the AECOPD  [6–8] . There is a direct 
correlation between the number of severe AECOPDs and 
the mortality rate among hospitalized patients with 
COPD  [9] . The administration of noninvasive ventilation 
(NIV) to hypercapnic patients decreases the mortality 
rate by 21%  [10] , which strongly suggests that in-hospital 
management directly influences the prognosis of patients 
with severe AECOPD. Therefore, it is of paramount im-
portance to provide adequate and comprehensive treat-
ment to this severely affected patient population.
 The European COPD Audit initiated by the European 
Respiratory Society (ERS) in collaboration with the Fo-
rum of European Respiratory Societies (FERS) aimed to 
monitor the management of severe AECOPD in 13 Euro-
pean countries (Austria, Belgium, Croatia, Greece, Malta, 
Poland, Ireland, Romania, Slovakia, Spain, Switzerland, 
Turkey, and the UK)  [11–13] . In Switzerland, patients 
were recruited from 19 hospitals distributed throughout 
13 Swiss cantons.
 Data on the management of AECOPD in Switzerland 
are scarce. Thus, the aim of this study was to examine the 
quality of care for AECOPD in Swiss hospitals in light of 
the GOLD 2010 guidelines and to provide specific recom-
mendations for the management of severe AECOPD in 
Switzerland.
 Materials and Methods 
 The study was classified as a quality control study by the Ethics 
Committee of Basel (307/10), and as such, no patient consent was 
required.
 The full methodology of the study has been reported  [12] . Pa-
tients requiring hospital admission due to AECOPD during a pre-
defined 2-month period in 2011 at 19 Swiss hospitals (Kantons-
spital Aarau, Universitätsspital Basel, St. Claraspital Basel, Spital 
Bern-Tiefenau, Inselspital Bern, Kantonsspital Chur, Kantonsspi-
tal Liestal, Kantonsspital Bruderholz, Spitalzentrum Biel, Spital 
Laufenburg, Lungenpraxis Hirslanden – Klinik St. Anna Luzern, 
Luzerner Höhenklinik Montana, Zuger Kantonsspital, Bürger-
spital Solothurn, Kantonsspital St. Gallen, Spital Thun, Kantons-
spital Münsterlingen, GZO Spital Wetzikon, and Lungenzentrum 
Hirslanden Zürich) were considered eligible for the study. The in-
clusion and exclusion criteria have been reported previously  [12] . 
In short, patients who were admitted to the hospital for  ≥ 12 h with 
a senior clinician-made diagnosis of COPD exacerbation or any 
other synonym, confirmed at discharge by the investigator/audit 
lead, and patients who were admitted to the hospital for  ≥ 12 h with 
a respiratory cause of admission as indicated by the discharge re-
port and a history compatible with COPD were included in the 
study. Most of the Swiss hospitals from which patients were re-
cruited were located in the German-speaking areas of Switzerland. 
The hospital catchment population was 3,524,177 citizens  [12] .
 The cases were examined by a respiratory specialist in charge 
of the emergency ward. When an exacerbation was identified, de-
tailed demographic and medical history data were collected and 
entered into a Web-based application. Data collection and imputa-
tion were standardized and centrally managed by a trained profes-
sional. The follow-up period was 90 days.  Figure 1 depicts the flow-
chart for patient inclusion in the study.
 The following GOLD recommendations were investigated ac-
cording to the European COPD Audit Study data: (1) symptoms; 
(2) arterial blood gas results; (3) chest radiograph results; (4) med-
ical treatment; (5) oxygen therapy; and (6) type of mechanical ven-
tilation  [12] .
 Statistical Analysis 
 Differences in dichotomous variables were evaluated using the 
χ 2 test or Fisher’s exact test, as appropriate. Normally distributed 
parameters were analyzed using the Student  t test for equality of 
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means. All other continuously nonnormally distributed parame-
ters were evaluated using the nonparametric Mann-Whitney U 
test or the Kruskal-Wallis test, as appropriate.
 The Statistical Package for the Social Sciences (SSPS Inc., ver-
sion 19 and 23 for Windows) was used. All tests were two-tailed; a 
 p value of <0.05 was considered significant. The results are ex-
pressed as mean (standard deviation) or median and interquartile 
range, unless otherwise stated.
 Results 
 Patient Characteristics 
 A total of 307 Swiss patients were included in the da-
tabase, and the data on 295 patients were analyzed ( Fig. 1 ). 
Six of the discharged patients had been misdiagnosed, 1 
died, 1 left within the first 12 h of hospitalization, 3 were 
moved to a nonparticipating hospital, and 1 had an incor-
rect admission date. The other European countries in-
cluded 15,723 patients. The patient characteristics for 
Switzerland and the other European countries are pre-
sented in  Table 1 .
 In the Swiss cohort, there were 165 (55.9%) male pa-
tients, the mean age was 70.7 years (SD 12), the average 
body mass index was 25 (SD 6.5), and the mean forced 
expiratory volume in 1s (FEV 1 ) was 44.8% predicted (SD 
19). A total of 43.1% (122/283) of the Swiss patients with 
an AECOPD were classified as smokers at hospital admis-
sion, in contrast to 32.8% (4,890/14,898) in the other Eu-
ropean countries ( p < 0.001). The main symptoms in both 
the Swiss cohort and the cohorts of the other European 
countries were increased dyspnea (92.5 vs. 97.1%;  p < 
0.001) and increased sputum volume (49.3 vs. 68.9%;  p < 
0.001). Most of the patients requiring hospitalization for 
AECOPD suffered from GOLD stage III COPD (50.7% in 
Switzerland vs. 45.5% in Europe;  p = 0.391).
 The most frequent comorbidities are shown in  Figure 
2 . Congestive heart failure ( p < 0.001), metastatic solid 
malignancy ( p < 0.001), dementia ( p < 0.001), and renal 
disease ( p < 0.001) were significantly more common in 
the Swiss patients than in the patients from the other Eu-
ropean countries. Conversely, myocardial infarction ( p < 
0.001), cerebrovascular disease ( p = 0.006), and ulcer dis-
ease ( p = 0.011) were more common in the other Euro-
pean countries than in Switzerland.
 Organization and Resources 
 The organization and resources of the hospitals caring 
for AECOPD patients in Switzerland and in other coun-
tries of Europe are depicted in  Table 2 . The resources of the 
Swiss hospitals were superior or equivalent to those of the 
other European hospitals in several categories ( Table 2 ). 
NIV was available in 100% of the participating Swiss hos-
pitals compared to 86.9% of the hospitals in the other 
European countries ( p = 0.417). In 94.7% of the Swiss hos-
pitals, a high dependency unit was available, compared to 
47.1% of the hospitals in the other European countries 
( p = 0.001). In Switzerland, patients have access to a pul-
monary rehabilitation program in 89.5% of the participat-
ing hospitals, compared to 48.1% of the participating hos-
pitals in the other European countries ( p = 0.004). There 
were also significant differences in the types of rehabilita-
tion program offered, with home-based therapy being the 
most prominent program offered in Switzerland compared 
to the other European countries (68.4 vs. 4.8%). A hospital-
based program was the main therapy in the other Euro-
pean countries compared to Switzerland (17.7 vs. 5.3%).
Daily admitted hospital patients
Is the
admission
COPD related?
Provisional inclusion:
Record demographics
(n = 307)
Diagnosed COPD
exacerbation at
discharge?
Exclusion
No
No
Yes
Definite inclusion:
Record clinical variables
(n = 295)
90-day follow-up:
Record outcomes
(n = 279)
Died during admission
(n = 16)
Yes
 Fig. 1. Flowchart depicting patient inclusion. COPD, chronic ob-
structive pulmonary disease. 
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 Pharmacological Treatment for COPD 
before Admission, during Hospitalization, 
and after Discharge 
 The prescribed pharmacological therapy for COPD 
before, during, and after hospital admission in Switzer-
land and the other European countries is presented in 
 Table 3 . Differences were noted in the frequency of the-
ophylline administration before admission (3.7 vs. 16.6%; 
 p < 0.001), during hospitalization (1.0 vs. 14.5%;  p < 
0.001), and after discharge (3.1 vs. 20.2%;  p < 0.001) be-
 Table 1.  Patient characteristics
Characteristics Switzerland  Europe p
n or mean
(% or SD)
patients, n n or mean
(% or SD)
patients, n
Total patients 100% 295 98.2% 15,723 0.068
Age, years 70.7 (12.1) 295 70.8 (10.7) 15,721 0.915
Male gender 165 (55.9) 295 10,700 (68.1) 15,723 <0.001
Height, cm 166.8 (8.0) 251 165.7 (9.0) 9,307 0.046
Weight, kg 70.1 (18.6) 274 73.2 (18.8) 9,449 0.007
BMI 25.0 (6.5) 250 26.7 (6.4) 9,139 <0.001
Smoking status    
Smoker 122 (43.1) 283 4,890 (32.8) 14,898 <0.001
Ex-smoker 138 (48.8) 283 9,179 (61.6) 14,898 <0.001
Never-smoker 23 (8.3) 283 829 (5.6) 14,898 0.085
Pack-years 54.9 (24.3) 109 53.2 (28) 3,777 0.538
Symptoms     
Dyspnea increased 273 (92.5) 295 15,136 (97.1) 15,584 <0.001
Sputum increased 145 (49.3) 294 10,228 (68.9) 14,834 <0.001
Sputum color change 109 (37.8) 288 8,025 (56.0) 14,332 <0.001
ABGA     
Taken 238 (85.6) 278 12,953 (84.1) 15,397 <0.001
pH 7.40 (0.078) 233 7.40 (0.074) 12,808 0.813
HCO3, mmol/L 26.5 (4.7) 228 28.1 (5.2) 12,207 <0.001
pO2, kPa 9.4 (4.9) 237 8.6 (3.4) 12,826 0.015
pCO2, kPa 6.1 (2.1) 236 6.4 (2.2) 12,833 0.033
Spirometry     
FVC, % predicted 69.6 (21.4) 144 65.4 (20.4) 8,863 0.014
FEV1, % predicted 44.8 (19.0) 186 44.0 (17.4) 9,089 0.573
FEV1/FVC, % predicted 58.0 (16.7) 148 53.6 (15.3) 9,064 0.002
X-ray result     
Normal 59 (20) 295 3,496 (22.3) 15,700 0.0181
Bronchiectasis 5 (1.7) 295 867 (5.5) 15,700 0.007
Hyperinflation 76 (25.8) 295 5,331 (34.0) 15,700 0.007
Consolidation 71 (24.1) 295 2,898 (18.5) 15,700 0.013
Pleural effusion 29 (9.8) 295 426 (2.7) 15,700 <0.001
Lung cancer 5 (1.7) 295 394 (2.5) 15,700 0.175
GOLD stage     
1 5 (3.4) 148 190 (2.4) 8,057 0.45
2 31 (20.9) 148 2,144 (26.5) 8,057 0.12
3 75 (50.7) 148 3,662 (45.5) 8,057 0.391
4 37 (25) 148 2,061 (25.6) 8,057 0.775
 BMI, body mass index; ABGA, arterial blood gas analysis; FVC, forced vital capacity; FEV1, forced expiratory 
volume in 1 s.
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 Table 2. Organization and resources
Characteristics Switzerland Europe
n (%) hospitals, n n (%) hospitals, n p
ICU available 17 (89.5) 19 370 (91.4) 405 0.928
Spirometry available 18 (94.7) 19 400 (98.8) 405 0.471
Respiratory physician on call every day 15 (78.9) 19 195 (48.1) 405 0.061
Respiratory ward available 13 (68.4) 19 332 (82.0) 405 0.455
Respiratory team available 17 (89.5) 19 363 (89.6) 405 0.945
Respiratory outpatient clinic available 18 (94.7) 19 362 (89.8) 403 0.808
Respiratory outpatient clinic for COPD 13 (68.4) 19 248 (61.5) 403 0.717
Respiratory specialists available* 3.0 (2.1) 19 6.5 (6.9) 403 <0.001
Respiratory physiotherapists available* 5.8 (6.7) 19 1.9 (2.1) 403 0.02
Specialty triage for COPD operated 6 (31.6) 19 129 (32.0) 403 0.925
High dependency unit available* 18 (94.7) 19 190 (47.1) 403 0.001
Seen by physiotherapists* 79.2 (25.8) 12 52.3 (40.7) 336 0.004
Seen by a respiratory specialist 67.1 (30.7) 17 69.5 (33.7) 371 0.772
NIV available 19 (100) 19 359 (89.1) 403 0.417
Invasive mechanical ventilation available 17 (89.5) 19 303 (75.2) 403 0.469
Pulmonary rehabilitation program available* 17 (89.5) 19 194 (48.1) 403 0.004
Hospital-based pulmonary rehabilitation* 1 (5.3) 19 70 (17.7) 395 <0.001
Home-based pulmonary rehabilitation* 13 (68.4) 19 19 (4.8) 395 <0.001
Early discharge program available 7 (36.8) 19 128 (31.8) 403 0.875
Palliative care available 8 (42.1) 19 244 (60.5) 403 0.377
Long-term oxygen program available 18 (94.7) 19 351 (87.1) 403 0.692
ICU, intensive care unit; COPD, chronic obstructive pulmonary disease; NIV, noninvasive ventilation. * Significant.
Myocardial infarction*
0 5 10 15 20 25 30 35
Congestive heart failure*
Peripheral vascular disease
Cerebrovascular disease*
Dementia*
Connective tissue disease
Ulcer disease*
Mild liver disease
Moderate or severe liver disease
Any tumor*
Diabetes
Diabetes with end organ damage
Moderate or severe renal disease*
Metastatic solid malignancy*
AIDS
Malignant lymphoma
Hemiplegia
Leukemia
ଶ Switzerland, %   ଶ Europe, %   * Significant
 Fig. 2. The most frequent comorbidities 
with chronic obstructive pulmonary dis-
ease exacerbation. 
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tween Switzerland and the other European countries. 
There were also significant differences in the administra-
tion of short-acting β 2 -agonists before admission (34.6 vs. 
60.3%;  p < 0.001), during hospitalization (79.0 vs. 84.7%; 
 p = 0.007), and after discharge (39 vs. 56.9%;  p < 0.001) 
between Switzerland and the other European countries. 
Administration of systemic corticosteroids was signifi-
cantly higher before admission (26.4 vs. 18.5%;  p = 0.001) 
in Switzerland than in the other European countries, but 
it became higher during hospitalization (82.4 vs. 76.9%; 
 p = 0.015) and after discharge (51.5 vs. 43.7%;  p = 0.008) 
in the other European countries than in Switzerland ( Ta-
ble 3 ). In Switzerland, NIV support before admission (7.5 
vs. 2.6%;  p < 0.001), during hospitalization (33.3 vs. 13.4%; 
 p < 0.001), and after discharge (8.2 vs. 5.2%;  p = 0.033) was 
significantly higher than in the other European countries. 
At discharge, Swiss physicians less commonly prescribed 
the combination LABA/ICS (57.3 vs. 69.9%;  p < 0.001) 
and antibiotics (24.7 vs. 41.9%;  p < 0.001) as compared to 
the other European physicians.
 Table 4. Patient outcomes
Switzerland Europe p
n or mean (% or SD) patients, n n or mean (% or SD) patients, n
Length of stay, days* 11.3 (8.9) 294 8.7 (8.3) 15,687 <0.001
Readmission within 90 days* 71 (25.4) 279 5,278 (35.3) 14,949 0.003
Mortality during admission 16 (5.4) 295 774 (4.9) 15,723 0.694
Follow-up mortality* 8 (2.9) 279 934 (6.2) 14,949 0.028
Overall mortality 24 (8.1) 295 1,708 (10.9) 15,723 0.135
* Significant, p < 0.05.
 Table 3. Pharmacological treatment before and during hospital admission and after discharge
Treatment Switzerland
before
Europe
before
p Switzerland
during
Europe
during
p Switzerland
after
Europe
after
p
LABA + ICS 157 (53.2) 9,027 (57.4) 0.149 169 (57.3) 10,990 (69.9) <0.001
LABA 23 (7.8) 1,459 (9.3) 0.384 29 (9.8) 1,530 (9.7) 0.954
LAMA 132 (44.7) 7,319 (46.5) 0.538 166 (56.)3 9,428 (60) 0.2
Oral theophylline 11 (3.7) 2,606 (16.6) <0.001 9 (3.1) 3,170 (20.2) <0.001
IV theophylline 3 (1) 2,273 (14.5) <0.001
SABA 102 (34.6) 9,483 (60.3) <0.001 233 (79) 13,322 (84.7) 0.007 115 (39.0) 8,948 (56.9) <0.001
SAMA 80 (27.1) 4,202 (26.7) 0.88 221 (74.9) 12,185 (77.5) 0.293 95 (32.2) 3,861 (24.6) 0.003
Systemic
corticosteroids 78 (26.4) 2,907 (18.5) 0.001 227 (76.9) 12,960 (82.4) 0.015 129 (43.7) 8,103 (51.5) 0.008
ICS 32 (10.8) 1,949 (12.4) 0.424 46 (15.6) 5,394 (34.1) <0.001 30 (10.2) 1,856 (11.8) 0.388
Antibiotics 54 (18.3) 3,148 (20) 0.465 214 (72.5) 13,559 (86.2) <0.001 73 (24.7) 6,581 (41.9) <0.001
Oxygen 51 (17.3) 3,905 (24.8) 0.003 258 (93.1) 13,344 (86.1) <0.001 85 (32.9) 5,173 (33.9) 0.76
Diuretics 73 (24.7) 4,159 (26.5) 0.51
IVS 14 (5.1) 272 (1.7) <0.001
NIV 22 (7.5) 416 (2.6) <0.001 92 (33.3) 2,043 (13.4) <0.001 21 (8.2) 793 (5.2) 0.033
No oxygen 173 (67.1) 10,139 (66.1) 0.062
Ambulatory oxygen 3 (1.2) 195 (1.3) 0.947
Long-term oxygen 81 (31.4) 4,660 (30.4) 0.496
Values are presented as n (%). LABA, long-acting β2-agonist; ICS, inhaled corticosteroids; LAMA, long-acting muscarinic antagonist 
(anticholinergic); SABA, short-acting β2-agonist; SAMA, short-acting muscarinic antagonist; IVS, invasive ventilatory support; NIV, 
noninvasive ventilatory support.
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 Implementation of the GOLD Recommendations for 
the Treatment of COPD Exacerbations 
 The implementation of the GOLD recommendations 
for AECOPD treatment in Switzerland and in other Eu-
ropean countries is presented in  Figure 3 . 
 1  Arterial blood gas (ABG) should be taken to assess the 
severity of the exacerbation. In 85.6% (238/278) of 
all admissions in Switzerland, an arterial blood gas 
analysis had been performed, compared to 84.1% 
(12,953/15,397) in the other European countries. The 
average partial oxygen pressure (PaO 2 ) was 9.4 kPa 
and the PaCO 2 was 6.1 kPa in Switzerland, compared 
to 8.6 kPa and 6.4 kPa, respectively, in the other Euro-
pean countries. 
 2  Spirometry results should be available on admission . 
64.0% (185/289) of the patients had spirometry results 
available at hospital admission in Switzerland, com-
pared to 59.1% (9,246/15,654) of the patients in the 
other European countries ( p = 0.057). 12.8% (37/289) 
of the Swiss patients and 7.6% (1,189/15,654) of the 
patients from the other European countries had a non-
obstructive FEV 1 /FVC >70% and were treated for ex-
acerbation ( p = 0.001). 
 3  Oxygen therapy should be offered on admission . In 
Switzerland, 93.1% (258/277) of the patients received 
oxygen therapy on admission, compared to 86.1% 
(13,344/15,492) of the patients in the other European 
countries ( p < 0.001). 94% of the Swiss patients had a 
pO 2 <8 kPa. Although there was no reported arterial 
blood sample taken, 7.2% (20/277) of these patients 
received oxygen. 
 4  Chest radiography should be performed at admission . 
In Switzerland, chest radiography was performed in 
97.3% (287/295) of all cases. In 26.5% (76/287) of 
these, hyperinflation was diagnosed, and in 1.7% 
(5/287) the chest X-ray revealed lung cancer; 20.6% 
(59/287) of the patients had a normal chest X-ray 
result and 24.7% (71/287) had consolidation. The 
results were similar in the other European countries 
( Table 1 ). 
 5  Short-acting β 2 -agonists should be used . A total of 79% 
(233/295) of the patients were treated with a short-act-
ing β 2 -agonist during hospitalization in Switzerland, 
as compared to 84.7% (13,322/15,723) patients in the 
other European countries ( p = 0.007). 
 6  Short-acting anticholinergics can be used as an addition 
to short-acting β 2 -agonists. 74.9% (221/295) of the pa-
tients were treated with short-acting anticholinergics 
during their hospitalization in Switzerland, as com-
pared to 77.5% (12,185/17,723) of the patients in the 
other European countries ( p = 0.293). 
 7  Inhaled or intravenous corticosteroids are recommend-
ed . 76.9% (227/295) of the patients received systemic 
corticosteroids and 15.6% (46/295) inhaled corticoste-
roids during hospitalization in Switzerland, as com-
pared to 82.4% (12,960/15,723) of the patients receiv-
ing systemic corticosteroids and 34.3% (5,396/15,723) 
inhaling corticosteroids in the other European coun-
tries ( p = 0.015 and  p < 0.001, respectively). 
 8  Antibiotic treatment is to be administered when a bac-
terial infection is suspected. In Switzerland, 72.5% 
(214/295) of the patients were treated with antibiotics 
during hospitalization. Amongst those patients who 
received antibiotics were 5 patients with sputum pu-
rulence and invasive mechanical ventilation (IMV) 
and 3 patients with no color change of the sputum, 
Arterial blood gas taken*
0 10 20 30 40 50 60 70 80 90 100
Spirometry results available*
Chest radiography taken*
Oxygen therapy*
Short-acting Ǆ2-agonist*
Short-acting anticholinergics
Systemic corticosteroids*
Antibiotics*
Methylxanthines i.v.*
NIV given if pH <7.35 and PaCO2 >6 kPa
IMV given if pH <7.25 and PaCO2 >8 kPa*
ଶ Switzerland, %   ଶ Europe, %   * Significant
Fig. 3. Implementation of GOLD recom-
mendations for the treatment of acute ex-
acerbation of chronic obstructive pulmo-
nary disease in Switzerland in comparison 
with other countries in Europe.
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nonincreased sputum, and nonincreased dyspnea. In 
the other European countries, 86.2% (13,559/15,723) 
of the patients received antibiotic treatment ( p < 
0.001). 
 9  Methylxanthines can be used as second-line therapy 
after short-acting bronchodilators . 1.0% (3/295) of the 
Swiss patients received methylxanthines; in the other 
European countries, 14.5% (2,273/15,723) of the pa-
tients were treated with this drug ( p = 0.001). 
 10  NIV or IMV should be considered . 33.3% (92/276) of 
the patients received noninvasive and 5.1% (14/276) 
received IMV. 36 patients (12.2%) in Switzerland ful-
filled the British Thoracic Society guidelines for NIV 
(pH <7.35 and pCO 2 >6 kPa)  [14] , and 66.7% of these 
patients received NIV, compared to 51.3% in the other 
European countries. 30% (3/10) of the patients who 
fulfilled the GOLD IMV criteria (pH <7.25 and pCO 2 
>8 kPa)  [4] received IMV treatment, compared to 
15.2% (70/461) in the rest of Europe. 
 Outcomes 
 The outcomes of the patients with severe AECOPD 
included in the audit in Switzerland and in the other Eu-
ropean countries are presented in  Table 4 . In Switzerland, 
the patients had a prolonged hospital length of stay (on 
average 11.3 vs. 8.7 days;  p < 0.001), but a lower 90-day 
readmission rate (25.4 vs. 35.3%;  p = 0.003). Although the 
overall mortality rate tended to be lower in Switzerland 
(8.1%) than in the other European countries (10.9%), 
Switzerland had a slightly higher rate of in-hospital deaths 
(5.4%) than the other European countries (4.9%).
 Discussion 
 The European COPD Audit provided a unique over-
view of the management of exacerbations of COPD and 
their outcomes in Europe. The Swiss COPD Audit com-
prised 19 hospitals, thus representing the only available 
multicenter study in the country focusing specifically 
on the management of COPD exacerbations. Although 
the number of patients included was relatively modest 
and represented only 50% of the Swiss population, the 
Swiss COPD Audit offered objective data for the forma-
tion of action plans for exacerbation care in Switzer-
land.
 A reliable diagnosis and accurate therapy are essential 
to improve patient outcomes after COPD exacerbation 
 [4] . The diagnosis of COPD and the clinical diagnosis of 
exacerbation of COPD both benefit from spirometric in-
formation. The absence of this information at admission 
may lead to incorrect diagnosis and treatment especially, 
since spirometry is not recommended during an acute 
exacerbation  [4] . That said, 36% of the Swiss patients did 
not have any spirometry results available at admission, 
although the Swiss hospitals were better equipped than 
those of the other European countries.
 Pulmonary rehabilitation improves the exercise ca-
pacity and quality of life of a patient  [15] . Although pul-
monary rehabilitation was available in 89.5% of all Swiss 
hospitals, only 40% of the patients took advantage of this 
therapeutic option. This could be attributed to the follow-
ing: (1) pulmonary rehabilitation is not reimbursed by 
health insurance for any patients with mild disease; (2) 
pulmonary rehabilitation is offered as ambulatory treat-
ment and many patients are too sick with too many co-
morbidities to be able to attend; and/or (3) physicians do 
not prescribe the rehabilitation program.
 Evaluation of the severity of an exacerbation requires 
a blood gas analysis, particularly in those patients with 
hypoxemia as evidenced by transcutaneous oximetry 
 [4] . It is especially striking that although a blood gas 
analysis is recommended in the GOLD guidelines  [1] , 
this examination was performed on only 85.6% of the 
patients fulfilling the criteria for severe exacerbation and 
thus requiring hospitalization. NIV reduces the mortal-
ity rate and the length of ICU and hospital stay  [16] ; yet 
only 66.7% of the patients fulfilling the ABG criteria for 
NIV received this therapy, and only 30.0% of those re-
quiring IMV were treated accordingly. In the other Eu-
ropean countries, NIV was administered to only 51.3% 
of the patients fulfilling the ABG criteria, and IMV to 
only 15.2% of the patients. NIV was, however, only 
available in 89.1% of the hospitals in the other European 
countries, and this could partly account for the lack of 
administration of this treatment in those countries. In 
Switzerland, NIV was available in all the participating 
hospitals.
 Antibiotic use was significantly lower in the Swiss hos-
pitals during hospitalization and after discharge, com-
pared to the rest of Europe. The GOLD guidelines state 
that antibiotics should be administered when a bacterial 
infection is suspected  [1] . With the increased usage of 
faster and more efficient molecular techniques, such as 
polymerase chain reaction, for detecting the type and 
presence of bacterial infections, as well as the use of cir-
culating blood C-reactive protein (CRP) and procalcito-
nin (PCT) levels for determining the initiation of anti-
biotic administration, antibiotic usage can be decreased 
 [17, 18] . In view of the threat of an increase in antibiotic-
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resistant bacteria, less antibiotic usage during an exacer-
bation of COPD should be considered by the other Euro-
pean countries.
 Administration of systemic corticosteroids before 
hospital admission was significantly higher in Switzer-
land than in the other European countries, but during 
hospitalization and after discharge, the Swiss patients 
were administered less systemic corticosteroids than the 
patients in the other European countries. The increased 
use of corticosteroids before admission may be due to the 
national model of care in Switzerland, where most pa-
tients referred for hospital admission have already been 
seen and have usually been treated by their general prac-
titioner.
 In accordance with the GOLD report 2010, fewer 
methylxanthines were used as a treatment option in Swit-
zerland compared to the other European countries. Al-
though more methylxanthines were used in the other Eu-
ropean countries, the 90-day readmission and follow-up 
mortality rates were significantly higher than in Switzer-
land. According to the GOLD recommendations, the 
beneficial effects of methylxanthines on lung function 
and other clinical end points are modest and inconsistent 
 [1] . Recent data showing the effects of methylxanthines 
on inflammation and fibrosis may account for the in-
creased use of methylxanthines in the other European 
countries  [19–21] .
 More Swiss patients had consolidation than had pa-
tients from the other European countries. Saleh et al.  [22] 
found that patients with COPD exacerbation who have 
consolidation have a more severe disease and worse prog-
nosis than patients without consolidation. This could ac-
count for the longer hospital stay experienced by the 
Swiss patients compared to the patients from the other 
European countries.
 There were significant differences in the prevalence of 
comorbidities between the Swiss patients and the patients 
from the other European countries. These differences 
may be due to differences in the complexity of workups 
in the various health-care systems across Europe. Since 
there are so many significant differences in treatment be-
fore and during hospitalization, it is difficult to determine 
which aspect of the treatment resulted in longer hospital-
ization, decreased readmission, and decreased follow-up 
mortality. It is also possible that these differences merely 
reflect different health-care models, as the length of hos-
pital stay is not only determined by the severity of the 
disease but also by social and logistic factors facilitating 
home or institutional care.
 Swiss Recommendations for an Action Plan for 
AECOPDs 
 Based on the available literature, collected data, and 
workshops involving respiratory physicians (hospital 
managers) representing all recruiting institutions, the fol-
lowing recommendations were established for the man-
agement of exacerbations of COPD in Switzerland. It is 
important to note that these recommendations may not 
be generalizable to all institutions in Switzerland.
 1 Smoking cessation and vaccination information 
should be offered to COPD patients admitted to the 
hospital for exacerbation. Patients should be offered 
smoking cessation counselling and information re-
garding influenza and pneumococcal vaccination ev-
ery time they are admitted to the hospital with an 
exacerbation. However, at the moment there is no re-
imbursement for non-physician smoking cessation 
counselling in the Swiss health care system, which may 
deter the introduction of this action  [23] . We, there-
fore, additionally recommend including non-physi-
cian smoking cessation support in the Swiss tariff 
system and the fostering of a closer cooperation with 
the Swiss lung organization (Lungenliga). 
 2 ABG or venous blood gas should be measured. Pa-
tients’ blood gas should be evaluated at presentation. 
The treatment and the diagnosis of exacerbation of 
COPD are very dependent on the blood gas analysis 
results; thus, for every patient with suspicion of severe 
exacerbation of COPD, we recommend that at least a 
venous blood gas analysis be performed  [24, 25] . 
 3 Medical staff should be trained in administering 
bronchodilators through a nebulizer with oxygen 
in the emergency ward. Patients should be offered 
oxygen at presentation. The cornerstone of treatment 
for AECOPD is bronchodilation with short-acting 
β 2 -agonists at an increased dosis and frequency  [4] . 
Medical staff should be trained in administering 
bronchodilators through a nebulizer with oxygen in 
the emergency ward to facilitate fast and correct 
therapy. 
 4 Systemic steroids should be administered. Patients 
should receive systemic steroids. Systemic steroids are 
efficient in the treatment of AECOPD, and they should 
be administered if there is a reasonable suspicion for 
an AECOPD. They reduce the recovery time of FEV 1 , 
hospital length of stay, and mortality rate  [26] . The 
main effect of the steroids shows in the first 72 h of ex-
acerbation. Based on the newest literature, we recom-
mend a dose of 20–60 mg prednisone for 5 days  [3, 
27–29] . 
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 5 Antibiotics should be given to patients with increased 
sputum volume, purulent sputum, and increased 
CRP or PCT, and to patients requiring ICU admis-
sion. Patients should receive antibiotics only in select-
ed cases. Antibiotic treatment is effective only in a 
small subgroup of patients with exacerbations. Indica-
tions for antibiotic administration include: increased 
sputum volume, sputum color, and purulence; need for 
ventilator support; or need for ICU transfer  [30, 31] . In 
addition to the clinical condition of the patient, circu-
lating CRP and PCT levels (e.g. >50 mg/dL and >0.25 
μg/L, respectively) should be evaluated to determine 
whether to initiate antibiotic treatment  [17, 18] . 
 6 NIV is indicated if pH <7.35 and pCO 2 >6 kPa. Pa-
tients should receive ventilator support if pH <7.35 
and pCO 2 >6 kPa. NIV should be administered as soon 
as possible when clinical and functional signs of acute 
respiratory distress are evident  [32–36] . In this study, 
it was found that patients administered NIV had a sur-
vival probability of 80.4%, compared to 64.4% of the 
patients treated with IMV  [37] . NIV therapy outside 
the emergency ward or ICU is, however, challenging 
in Swiss hospitals, and these challenges will need to be 
addressed before this recommendation can be imple-
mented. 
 7 Spirometry should be performed before discharging 
a patient or at least 4–6 weeks thereafter. Patients’ 
lung function should be evaluated before discharge, or 
at least 4–6 weeks after discharge if this information is 
not available  [36] . 
 The European COPD Audit has some limitations, 
such as the lack of information on mucolytics and the vac-
cination status of the patients. Moreover, the recom-
mended FEV 1 /FVC quotient for diagnosing COPD could 
overestimate the prevalence of the disease, particularly 
among elderly people.
 In conclusion, considering the overall high standard of 
health care in Switzerland and in light of the GOLD 2010 
guidelines, we were able to make 7 recommendations 
to improve and standardize the management of severe 
AECOPD for patients treated in Switzerland.
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